Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty

Hamon, Martial; Lecluse, E.; Monassier, Jean‐Pierre; Grollier, Gilles; Potier, J C

doi:10.2165/00002512-199813040-00005

Cited by 25 publications

(13 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, drugs with antiproliferative properties have been intensively investigated to prevent restenosis. However, systemic drug therapy has shown diminished efficacy, narrow therapeutic ranges and poor tolerance [3]. Consequently, intraluminal drug delivery devices, particularly drug-eluting stents (DESs), are being used to prevent restenosis as they slowly and locally release drugs to block cell proliferation [1].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Autophagy by Everolimus Contributes to the Antirestenotic Mechanisms in Vascular Smooth Muscle Cells

Tang

Dong²,

Wei³

et al. 2014

J Vasc Res

View full text Add to dashboard Cite

Objective: The present study aims to investigate the underlying mechanisms accounting for the activities of everolimus to inhibit the growth of vascular smooth muscle cells (VSMCs), which contributes to restenosis. Methods: Primary VSMCs were cultured in media containing smooth muscle growth supplements and incubated with testing agents. Cell proliferation, cell cycle distribution, apoptosis and autophagy, and the key molecules involved, were examined. Results: Everolimus inhibited the proliferation of VSMCs by inhibiting the activation of ribosomal protein S6 kinase and phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1, and downregulating proliferating cellular nuclear antigen. Everolimus induced cell cycle arrest at the G₁ phase by downregulating cyclin D1 and upregulating p27, and increased apoptosis by downregulating Bcl-2, upregulating Bad and activating capsase-3 and poly ADP ribose polymerase. Everolimus enhanced autophagy by increasing the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II, and upregulating Beclin 1. Specific autophagy inhibitors, 3-methyladenine and bafilomycin A1, significantly attenuated the inhibition of cell proliferation, the increased apoptosis and the altered expression of the above key proteins induced by everolimus. Conclusions: Enhanced autophagy by everolimus contributes to its antirestenotic activity and its abilities to inhibit cell proliferation and to induce apoptosis of VSMCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced Autophagy by Everolimus Contributes to the Antirestenotic Mechanisms in Vascular Smooth Muscle Cells

Tang

Dong²,

Wei³

et al. 2014

J Vasc Res

View full text Add to dashboard Cite

show abstract

“…[2021] Although different therapeutic strategies have been investigated for the inhibition of restenosis, the main drug therapy approach is targeted toward inhibiting the proliferation and migration of smooth muscle cells. [22]…”

Section: Restenosismentioning

confidence: 99%

Current status of nanomedicine and nanosurgery

Singh

2013

Anesth Essays Res

View full text Add to dashboard Cite

Nanotechnology is a multidisciplinary field that covers a vast and diverse array of devices derived from physics, biology, engineering, and chemistry. Applications of nanotechnology to medicine and physiology imply materials and devices designed to interact with the body at subcellular (i.e., molecular) scales with a high degree of specificity. There is considerable useful information about nanotechnology available and already in use. However, at present, it is very incomplete and scattered. We realized many doctors are unaware of nanotechnology used during surgery and its future prospects in patients. Though most medical products that use nanotechnology are still in the research and development stage, there are a few which are commercially available. Nanotechnology has grown by leaps and bounds over the last few years; applications of this technology in the field of medicine and surgery have been an important spin-off. Many biological structures are at nanometer scale used by surgeons in orthopedic, dental, and neurosurgeries. This article starts with the basics of the nanotechnology and how it is utilized through most medical products. This important article, which is felt to offer high educational value for the doctors, have been selected from an extensive search on the internet, and elaborately discussed. In this review, the scientific and technical aspects of nanotechnology are introduced, and some of its potential clinical applications are discussed.

show abstract

“…These include anticoagulatory, antithrombotic and antiplatelet agents (e.g., heparin, ridogrel); anti-inflammatory agents (e.g., dexamethasone, tranilast); antiproliferative drugs and growth factor antagonists (e.g., trapidil, tyrphostin, angiotensin-converting enzyme (ACE) inhibitors); cytostatic drugs (e.g., paclitaxel, rapamycin); lipid-lowering agents (e.g., statins); and antioxidants (e.g., probucol, resveratrol) [10,18,115,[146][147][148][149][150][151].…”

Section: Targeted Therapiesmentioning

confidence: 99%

“…Although effective in reducing neointimal formation in animal models [39,222], it has conflicting clinical effects when given systemically. Although it reduced the incidence of restenosis in a preliminary trial, it was not effective as an antirestenotic agent in a larger trial [148,149]. However, small trials of locally delivered angiopeptin (stent-delivered or catheterdelivered) are more promising [113,223].…”

Section: Antiproliferative and Antimigrating Agentsmentioning

confidence: 99%

Targeted Treatments for Restenosis and Vein Graft Disease

Thomas

2012

ISRN Vascular Medicine

View full text Add to dashboard Cite

Surgery to restore blood flow in arteries blocked by atherosclerotic plaque is a common treatment in cardiovascular disease. Longterm complications of surgical treatment are vein graft disease and restenosis, a renarrowing of the blood vessel after bypass or removal of the culprit atherosclerotic plaque. Attempts to prevent or treat these complications by systemic pharmacological approaches have been largely unsuccessful in the clinic. This has led to an interest in developing targeted or locally delivered strategies. This paper discusses many of the various site-delivered therapies that are under examination as potential antirestenotic and antivein graft disease agents (including antithrombotic, antiproliferative, and anti-inflammatory agents) and why many therapies developed in animal models fail in clinical trials. Techniques of targeted delivery (including stents, "magic bullets," and adventitial delivery) and delivery systems (including nanoparticles and the use of gene therapy) are also discussed.

show abstract

Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty

Cited by 25 publications

References 87 publications

Enhanced Autophagy by Everolimus Contributes to the Antirestenotic Mechanisms in Vascular Smooth Muscle Cells

Enhanced Autophagy by Everolimus Contributes to the Antirestenotic Mechanisms in Vascular Smooth Muscle Cells

Current status of nanomedicine and nanosurgery

Targeted Treatments for Restenosis and Vein Graft Disease

Contact Info

Product

Resources

About